{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:48:00Z","timestamp":1790117280255,"version":"4.0.1"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00059"],"award-info":[{"award-number":["PI18\/00059"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00185"],"award-info":[{"award-number":["PI23\/00185"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RETIC RD16\/0009\/0011"],"award-info":[{"award-number":["RETIC RD16\/0009\/0011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["IJC2018-037792-I"],"award-info":[{"award-number":["IJC2018-037792-I"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda","award":["PI18\/00059"],"award-info":[{"award-number":["PI18\/00059"]}]},{"name":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda","award":["PI23\/00185"],"award-info":[{"award-number":["PI23\/00185"]}]},{"name":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda","award":["RETIC RD16\/0009\/0011"],"award-info":[{"award-number":["RETIC RD16\/0009\/0011"]}]},{"name":"Fundaci\u00f3n Espa\u00f1ola de Reumatolog\u00eda","award":["IJC2018-037792-I"],"award-info":[{"award-number":["IJC2018-037792-I"]}]},{"DOI":"10.13039\/501100004837","name":"Diputaci\u00f3 de Lleida and Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI18\/00059"],"award-info":[{"award-number":["PI18\/00059"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Diputaci\u00f3 de Lleida and Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PI23\/00185"],"award-info":[{"award-number":["PI23\/00185"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Diputaci\u00f3 de Lleida and Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RETIC RD16\/0009\/0011"],"award-info":[{"award-number":["RETIC RD16\/0009\/0011"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Diputaci\u00f3 de Lleida and Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["IJC2018-037792-I"],"award-info":[{"award-number":["IJC2018-037792-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Societat Catalana de Reumatologia","award":["PI18\/00059"],"award-info":[{"award-number":["PI18\/00059"]}]},{"name":"Societat Catalana de Reumatologia","award":["PI23\/00185"],"award-info":[{"award-number":["PI23\/00185"]}]},{"name":"Societat Catalana de Reumatologia","award":["RETIC RD16\/0009\/0011"],"award-info":[{"award-number":["RETIC RD16\/0009\/0011"]}]},{"name":"Societat Catalana de Reumatologia","award":["IJC2018-037792-I"],"award-info":[{"award-number":["IJC2018-037792-I"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Advanced glycation end-products (AGEs) may play a relevant role as inducers in the chronic inflammatory pathway present in immune-mediated diseases, such as systemic lupus erythematosus (SLE). AGEs concentrations have been associated, with discrepant results to date, with some parameters such as disease activity or accrual damage, suggesting their potential usefulness as biomarkers of the disease. Our objectives are to confirm differences in AGEs levels measured by cutaneous autofluorescence between SLE patients and healthy controls (HC) and to study their correlation with various disease parameters. Cross-sectional study, where AGEs levels were measured by skin autofluorescence, and SLE patients\u2019 data were compared with those of sex- and age-matched HC in a 1:3 proportion through a multiple linear regression model. Associations of AGEs levels with demographic and clinical data were analyzed through ANOVA tests. Both analyses were adjusted for confounders. AGEs levels in SLE patients were significantly higher than in HC (p &lt; 0.001). We found statistically significant positive associations with SLE disease activity index (SLEDAI) and damage index (SDI), physician and patient global assessment, C-reactive protein, leukocyturia, complement C4, IL-6 and oral ulcers. We also found a negative statistically significant association with current positivity of anti-nuclear and anti-Ro60 antibodies. AGEs seem to have a contribution in LES pathophysiology, being associated with activity and damage and having a role as a new management and prognosis biomarker in this disease. The association with specific antibodies and disease manifestations may indicate a specific clinical phenotype related to higher or lower AGEs levels.<\/jats:p>","DOI":"10.3390\/ijms25053022","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:26:59Z","timestamp":1709638019000},"page":"3022","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Role of Advanced Glycation End Products as New Biomarkers in Systemic Lupus Erythematosus"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-3954","authenticated-orcid":false,"given":"Irene","family":"Carri\u00f3n-Barber\u00e0","sequence":"first","affiliation":[{"name":"Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Medicine Department, Medicine Faculty, Universitat Aut\u00f2noma de Barcelona, 08193 Bellaterra, Spain"},{"name":"Inflammation and Cartilage Cellular Research Group, Hospital del Mar Research Institute (IMIM), C\/Dr. Aig\u00fcader 88, 08003 Barcelona, Spain"},{"name":"Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2224-2987","authenticated-orcid":false,"given":"Laura","family":"Triginer","sequence":"additional","affiliation":[{"name":"Inflammation and Cartilage Cellular Research Group, Hospital del Mar Research Institute (IMIM), C\/Dr. Aig\u00fcader 88, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1408-7381","authenticated-orcid":false,"given":"Laura","family":"T\u00edo","sequence":"additional","affiliation":[{"name":"Inflammation and Cartilage Cellular Research Group, Hospital del Mar Research Institute (IMIM), C\/Dr. Aig\u00fcader 88, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Inflammation and Cartilage Cellular Research Group, Hospital del Mar Research Institute (IMIM), C\/Dr. Aig\u00fcader 88, 08003 Barcelona, Spain"},{"name":"Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-7230","authenticated-orcid":false,"given":"Anna","family":"Ribes","sequence":"additional","affiliation":[{"name":"Inflammation and Cartilage Cellular Research Group, Hospital del Mar Research Institute (IMIM), C\/Dr. Aig\u00fcader 88, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Abad","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pros","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-4158","authenticated-orcid":false,"given":"Marcelino","family":"Berm\u00fadez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n Translacional Vascular y Renal, IRBLleida, 25198 Lleida, Spain"},{"name":"Departament de Medicina Experimental, Universitat de Lleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Castro-Boqu\u00e9","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n Translacional Vascular y Renal, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9684-0183","authenticated-orcid":false,"given":"Albert","family":"Lecube","sequence":"additional","affiliation":[{"name":"Departament d\u2019Endocrinologia i Nutrici\u00f3, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain"},{"name":"Grup de Recerca Obesitat i Metabolisme (ODIM), IRBLleida, Universitat de Lleida, 25198 Lleida, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-0184","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Valdivielso","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n Translacional Vascular y Renal, IRBLleida, 25198 Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ILERVAS Project Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Monfort","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Inflammation and Cartilage Cellular Research Group, Hospital del Mar Research Institute (IMIM), C\/Dr. Aig\u00fcader 88, 08003 Barcelona, Spain"},{"name":"Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek Carlos","family":"Salman-Monte","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Inflammation and Cartilage Cellular Research Group, Hospital del Mar Research Institute (IMIM), C\/Dr. Aig\u00fcader 88, 08003 Barcelona, Spain"},{"name":"Clinical Expertise Unit (UEC) in Systemic Autoimmune Diseases and Vasculitis, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.kint.2017.11.034","article-title":"Advanced Glycation End Products in the Pathogenesis of Chronic Kidney Disease","volume":"93","author":"Rabbani","year":"2018","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.freeradbiomed.2006.05.020","article-title":"Oxidatively Modified Autoantigens in Autoimmune Diseases","volume":"41","author":"Kurien","year":"2006","journal-title":"Free Radic. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R817","DOI":"10.1186\/ar1749","article-title":"Decreased Levels of Soluble Receptor for Advanced Glycation End Products in Patients with Rheumatoid Arthritis Indicating Deficient Inflammatory Control","volume":"7","author":"Pullerits","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE Signaling in Inflammatory Disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37525","DOI":"10.1074\/jbc.M111.223438","article-title":"Solution Structure of the Soluble Receptor for Advanced Glycation End Products (SRAGE)","volume":"286","author":"Ikonen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2174\/092986706777585013","article-title":"Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target","volume":"13","author":"Geroldi","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/rheumatology\/ken302","article-title":"Skin Autofluorescence Is Increased in Systemic Lupus Erythematosus but Is Not Reflected by Elevated Plasma Levels of Advanced Glycation Endproducts","volume":"47","author":"Nienhuis","year":"2008","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00726-003-0017-9","article-title":"Maillard Reaction Products in Tissue Proteins: New Products and New Perspectives","volume":"25","author":"Thorpe","year":"2003","journal-title":"Amino Acids"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcjd.2022.09.074","article-title":"Skin and Serum Advanced Glycation End Products in Adults With Type 1 Diabetes","volume":"46","author":"Coll","year":"2022","journal-title":"Can. J. Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00125-004-1451-2","article-title":"Simple Non-Invasive Assessment of Advanced Glycation Endproduct Accumulation","volume":"47","author":"Meerwaldt","year":"2004","journal-title":"Diabetologia"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nowak, A., Przywara-Chowaniec, B., Damasiewicz-Bodzek, A., Blachut, D., Nowalany-Kozielska, E., and Tyrpie\u0144-Golder, K. (2021). Advanced Glycation End-Products (Ages) and Their Soluble Receptor (Srage) in Women Suffering from Systemic Lupus Erythematosus (Sle). Cells, 10.","DOI":"10.3390\/cells10123523"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ene, C.D., Georgescu, S.R., Tampa, M., Matei, C., Mitran, C.I., Mitran, M.I., Penescu, M.N., and Nicolae, I. (2021). Cellular Response against Oxidative Stress, a Novel Insight into Lupus Nephritis Pathogenesis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080693"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, D.Y., Chen, Y.M., Lin, C.C., Hsieh, C.W., Wu, Y.C., Hung, W.T., Chen, H.H., and Lan, J.L. (2015). The Potential Role of Advanced Glycation End Products (AGEs) and Soluble Receptors for AGEs (SRAGE) in the Pathogenesis of Adult-Onset Still\u2019s Disease. BMC Musculoskelet. Disord., 16.","DOI":"10.1186\/s12891-015-0569-3"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R181","DOI":"10.1186\/ar3145","article-title":"Small Artery Elasticity Is Decreased in Patients with Systemic Lupus Erythematosus without Increased Intima Media Thickness","volume":"12","author":"Nienhuis","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/rheumatology\/kem215","article-title":"Accumulation of Advanced Glycation Endproducts in Patients with Systemic Lupus Erythematosus","volume":"46","author":"Graaff","year":"2007","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/CIRCULATIONAHA.106.648139","article-title":"Inflamed Joints and Stiff Arteries","volume":"114","author":"Quyyumi","year":"2006","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndt\/11.supp5.31","article-title":"The Role of Advanced Glycosylation End-Products in the Pathogenesis of Atherosclerosis","volume":"11","author":"Makita","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vekic, J., Vujcic, S., Bufan, B., Bojanin, D., Al-Hashmi, K., Al-Rasadi, K., Stoian, A.P., Zeljkovic, A., and Rizzo, M. (2023). The Role of Advanced Glycation End Products on Dyslipidemia. Metabolites, 13.","DOI":"10.3390\/metabo13010077"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203306069972","article-title":"Traditional and Non-Traditional Risk Factors Contribute to the Development of Accelerated Atherosclerosis in Patients with Systemic Lupus Erythematosus","volume":"15","author":"Freire","year":"2006","journal-title":"Lupus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR Evidence-Based Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Forms of Inflammatory Arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1177\/09612033221122158","article-title":"Serologic Phenotypes Distinguish Systemic Lupus Erythematosus Patients Developing Interstitial Lung Disease and\/or Myositis","volume":"31","author":"Cotton","year":"2022","journal-title":"Lupus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0272-6386(00)70189-2","article-title":"Advanced Glycation End Products: A Nephrologist\u2019s Perspective","volume":"35","author":"Raj","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/164_2020_391","article-title":"Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation","volume":"264","author":"Sourris","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jada.2004.05.214","article-title":"Advanced Glycoxidation End Products in Commonly Consumed Foods","volume":"104","author":"Goldberg","year":"2004","journal-title":"J. Am. Diet. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","article-title":"A Review of Complement Activation in SLE","volume":"23","author":"Weinstein","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e000209","DOI":"10.1136\/lupus-2017-000209","article-title":"Complement Levels and Risk of Organ Involvement in Patients with Systemic Lupus Erythematosus","volume":"4","author":"Gandino","year":"2017","journal-title":"Lupus Sci. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10067-014-2843-4","article-title":"Diagnostic Value of Serum Complement C3 and C4 Levels in Chinese Patients with Systemic Lupus Erythematosus","volume":"34","author":"Li","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s13258-022-01308-y","article-title":"The Inflammatory Signature in Monocytes of Sj\u00f6gren\u2019s Syndrome and Systemic Lupus Erythematosus, Revealed by the Integrated Reactome and Drug Target Analysis","volume":"44","author":"Lee","year":"2022","journal-title":"Genes Genom."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00296-008-0529-4","article-title":"Decreased Levels of Soluble Receptor for Advanced Glycation End Products in Patients with Primary Sj\u00f6gren\u2019s Syndrome","volume":"28","author":"Stewart","year":"2008","journal-title":"Rheumatol. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/03009740310004775","article-title":"Receptor of Advanced Glycation End Product (RAGE) Expression in the Minor Salivary Glands of Patients with Sj\u00f6gren\u2019s Syndrome: A Preliminary Study","volume":"33","author":"Katz","year":"2004","journal-title":"Scand. J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/acr.23420","article-title":"Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations with Extraglandular Involvement and Disease Activity in Sj\u00f6gren\u2019s Syndrome","volume":"70","author":"Kanne","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New Insights into the Role of Antinuclear Antibodies in Systemic Lupus Erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_35","unstructured":"(2023, September 05). Available online: https:\/\/Elbusdelasalut.Cat\/Professionals\/Protocol-Estudi\/."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Shardlow, A., McIntyre, N.J., Kolhe, N.V., Nellums, L.B., Fluck, R.J., McIntyre, C.W., and Taal, M.W. (2020). The Association of Skin Autofluorescence with Cardiovascular Events and All-Cause Mortality in Persons with Chronic Kidney Disease Stage 3: A Prospective Cohort Study. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003163"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/3022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:41Z","timestamp":1760105381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/3022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25053022"],"URL":"https:\/\/doi.org\/10.3390\/ijms25053022","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}